Chromogranin A (INACTIVE as of 08/17/20: Refer to 3002867 in the August Hotline)
Assay aids in monitoring but is not recommended for diagnosis of carcinoid tumors. Assay may be useful in monitoring nonsecretory sympathetic and parasympathetic neuroendocrine tumors.
Quantitative Enzyme Immunoassay
Mon, Wed, Fri
Serum separator tube or plain red.
Allow serum specimen to clot completely at room temperature. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 6 weeks
Effective August 19, 2019
This test is performed using the Cisbio CGA-ELISA-US kit. Results obtained with different methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.
Non-tumor related elevations of Chromogranin-A can be observed in gastrointestinal, cardiovascular, and renal disorders, as well as with proton pump inhibitor (PPI) therapy.
Compliance Statement D: For laboratory tests using a manufactured RUO kit. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
|Component Test Code*||Component Chart Name||LOINC|